Extended Data Fig. 9: The absence of Siglece enhances the efficacy of ICB therapy in murine GBM model. | Nature Cancer

Extended Data Fig. 9: The absence of Siglece enhances the efficacy of ICB therapy in murine GBM model.

From: Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response

Extended Data Fig. 9: The absence of Siglece enhances the efficacy of ICB therapy in murine GBM model.The alt text for this image may have been generated using AI.

(a) Schematic illustration of ICB therapy. WT or Siglece−/− mice were subcutaneously inoculated with CT2A glioma cells and the mice bearing tumors were administered intraperitoneally with anti-mouse PD-1, anti-mouse PD-L1 or left untreated on days 12, 16, 20, and 24. Tumor growth was monitored. (b, c, d and e) The subcutaneous tumor volume (b, d) and overall survival (c, e) of WT and Siglece−/− mice treated with anti-PD-1 (b, c), anti-PD-L1 (d, e) or left untreated after inoculation of CT2A cells. The numbers of mice are as indicated. Data are means ± SEM (b, d). Two-sided log-rank test. (f) Schematic illustration of Siglec-E-Fc therapy. WT mice were subcutaneously inoculated with CT2A glioma cells and the mice bearing tumors were administered intraperitoneally with Siglec-E-Fc or IgG. Tumor growth was monitored. (g) The subcutaneous tumor volume of WT mice treated with Siglec-E-Fc or IgG after inoculation of CT2A cells. The numbers of mice are as indicated. Data are means ± SEM. Two-sided log-rank test.

Source data

Back to article page